GlassScriptPhysician profile
Angel Perez
NPI 1477541662
$11,009.73
in general payments reported to CMS, 2019-2025
54 companies · $1,444 in 2025
The $1,444 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,813 · 2020: $2,119 · 2021: $1,595 · 2022: $1,182 · 2023: $1,355 · 2024: $1,502 · 2025: $1,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,301.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,156.84 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $961.10 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $791.19 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Pfizer INC. | $723.82 | 2019-2025 | |
| Novo Nordisk INC | $671.79 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $519.65 | 2019-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $503.28 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $439.01 | 2019-2022 | |
| Abbvie INC. | $429.98 | 2021-2025 | |
| Aytu Biopharma, INC. | $337.23 | 2019-2020 | |
| Esperion Therapeutics, INC. | $324.36 | 2020-2023 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $281.97 | 2024-2025 | |
| Exact Sciences Corporation | $265.98 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $225.49 | 2019-2025 | Xifaxan |
| Mylan Specialty L.P. | $167.46 | 2020-2022 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angel Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.